H.C. Wainwright placed the firm’s Buy rating on Ocuphire Pharma (OCUP) under review saying the acquisition of Opus Genetics starts a new chapter.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OCUP: